BeiGene, Ltd.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

An investigation is underway to determine whether the Company provided inaccurate or deceptive statements or failed to disclose important information that could affect investors. BeiGene has become the subject of an article published by Morningstar on June 15, 2023, titled “BeiGene experiences share price decline following patent infringement lawsuit by AbbVie unit over cancer drug.” As reported in the article, AbbVie’s (ABBV) Pharmacyclics unit has filed a lawsuit alleging patent infringement against BeiGene, specifically regarding their production and sale of Brukinsa, a treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma. The complaint, filed in federal court in Delaware on Tuesday, asserts that BeiGene’s Brukinsa infringes on Pharmacyclics’ patent for Imbruvica, which is also used to treat the same conditions. In January, Brukinsa received approval from the U.S. Food and Drug Administration for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. As a result of this news, BeiGene’s shares declined by 3.4% on the same day.